<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265288</url>
  </required_header>
  <id_info>
    <org_study_id>LAU-14-01</org_study_id>
    <nct_id>NCT03265288</nct_id>
  </id_info>
  <brief_title>Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults</brief_title>
  <acronym>APPLAUD</acronym>
  <official_title>APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laurent Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laurent Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the&#xD;
      safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the&#xD;
      safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.&#xD;
      All patients will remain on their CF standard-of-care treatments over the trial duration.&#xD;
&#xD;
      The goal for the treatment with LAU-7b in CF is to preserve lung function by reducing the&#xD;
      persistent inflammation in the lung and to improve its capacity to defend against resistant&#xD;
      bacteria such as Pseudomonas aeruginosa.&#xD;
&#xD;
      The treatment regimen will consist of 6 consecutive &quot;dosing cycles&quot; of 21 days each, spaced&#xD;
      by study drug-free periods of 7 days. A total of 136 eligible adult patients with CF will be&#xD;
      randomized to receive 300 mg LAU-7b or placebo in a 1:1 ratio. The participation in the study&#xD;
      will last about 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, parallel groups and placebo-controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be randomly assigned to take either the active drug (fenretinide capsule) or a matching inactive placebo (inactive capsule).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (FEV1%)</measure>
    <time_frame>From baseline to 24 weeks</time_frame>
    <description>Standardized, serial FEV1 measurements will be performed during the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of LAU-7b will be assessed by the incidence of treatment emergent adverse events compared to placebo</measure>
    <time_frame>From Baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial assessments and ad-hoc assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving normalization of the arachidonic acid, docosahexaenoic acid and their ratio in phospholipids</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and relative (%) change in FEV1 percent predicted at 3, 7, 11, 15 and 28 weeks into the trial</measure>
    <time_frame>From baseline to 3, 7, 11, 15 and 28 weeks into the trial</time_frame>
    <description>Standardized, serial FEV1 measurements will be performed during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first protocol-defined pulmonary exacerbation</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of protocol-defined pulmonary exacerbation</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first change and usage of antibiotic (other than chronic inhaled antibiotics already started prior to trial or oral chronic azithromycin)</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation and their treatment during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline of systemic markers of inflammation in blood</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from screening of the body weight and calculated Body Mass Index (BMI)</measure>
    <time_frame>From screening to 28 weeks</time_frame>
    <description>This will be assessed through serial weighing during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall change from screening of the Pseudomonas aeruginosa density (colony forming units) in the sputum</measure>
    <time_frame>From screening to Weeks 11 and 24</time_frame>
    <description>This will be assessed through induced sputum on 3 occasions during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact (from baseline) on overall health, daily life, perceived well-being and symptoms measured with the Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through administration of the questionnaire at planned times during the trial</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in metabolipidomic profile and in markers of oxidative stress in blood</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </other_outcome>
  <other_outcome>
    <measure>The change in metabolipidomic profile in blood, the systemic markers of inflammation in blood, the FEV1, the body weight and calculated BMI</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Only in patients who experience a pulmonary exacerbation requiring intravenous antibiotics, this will be assessed prior to- and after the intravenous antibiotic course.</description>
  </other_outcome>
  <other_outcome>
    <measure>The change from baseline of systemic bone formation and resorption biomarkers</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>This will be assessed through blood sampling on 2 occasions during the trial</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>LAU-7b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug fenretinide (as LAU-7b capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule (as inactive capsules identical to active arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAU-7b</intervention_name>
    <description>LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.</description>
    <arm_group_label>LAU-7b</arm_group_label>
    <other_name>fenretinide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening FEV1 between 40% and 100% predicted value for age, gender and height, in&#xD;
             patients capable of properly performing the test;&#xD;
&#xD;
          -  History of pulmonary exacerbation, defined as at least one (1) pulmonary exacerbation&#xD;
             in the year prior to Screening which resulted in documented intravenous or Oral&#xD;
             antibiotics;&#xD;
&#xD;
          -  Patients are eligible independently of their history of pulmonary Pseudomonas&#xD;
             aeruginosa (PsA) infection and their PsA status at screening;&#xD;
&#xD;
          -  If taking Kalydeco® (ivacaftor), Orkambi® (ivacaftor/lumacaftor), Symdeko®&#xD;
             (ivacaftor/tezacaftor) or other commercially available CFTR modulator products,&#xD;
             patients must be taking it for a minimum of 3 months prior to screening if naïve to&#xD;
             CFTR modulators and 1 month if switched from another CFTR modulator product and deemed&#xD;
             to tolerate it;&#xD;
&#xD;
          -  No change in CF and allowed systemic chronic therapy for a minimum of 5 weeks prior to&#xD;
             randomization, of which 2 weeks minimum are prior to screening;&#xD;
&#xD;
          -  Female patients of child bearing potential should be on highly effective contraceptive&#xD;
             methods during the study;&#xD;
&#xD;
          -  Male patients with spouse or partner of child bearing potential, or pregnant, are&#xD;
             eligible if they use an appropriate method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy: due to the potential teratogenic effects of retinoids, pregnant women are&#xD;
             NOT eligible;&#xD;
&#xD;
          -  Breast milk feeding by study patient is NOT allowed;&#xD;
&#xD;
          -  Clinically abnormal renal function: serum creatinine &gt; 132 μM (1.5 mg/dL);&#xD;
&#xD;
          -  Clinically abnormal liver function: Total bilirubin &gt;1.5 x ULN (in the absence of&#xD;
             demonstrated Gilbert's syndrome), alanine aminotransferase (ALT) and/or aspartate&#xD;
             aminotransferase (AST) &gt; 2.5 x ULN;&#xD;
&#xD;
          -  Patients with plasma retinol levels below 0.7 µM;&#xD;
&#xD;
          -  Presence of nyctalopia or hemeralopia at enrolment, or any other serious retinal,&#xD;
             ophthalmological condition;&#xD;
&#xD;
          -  Presence of serious dermatological conditions at entry, including inflammatory or&#xD;
             xerotic skin pathologies such as psoriasis or ichthyosis;&#xD;
&#xD;
          -  Intake of chronic systemic steroids in the month prior to screening and during the&#xD;
             study;&#xD;
&#xD;
          -  History of acute infections (viral/bacterial/fungal) within 5 weeks prior to&#xD;
             randomization, of which 2 weeks minimum are prior to screening, whether or not treated&#xD;
             and resolved;&#xD;
&#xD;
          -  Presence of infection with Burkholderia cepacia (including all species within the&#xD;
             Burkholderia cepacia complex group, and Burkholderia gladioli) in the 12 months prior&#xD;
             to screening;&#xD;
&#xD;
          -  Patients with a confirmed diagnosis (as per the Cystic Fibrosis Foundation diagnostic&#xD;
             criteria) of Allergic BronchoPulmonary Aspergillosis (ABPA) and actively being treated&#xD;
             with corticosteroids and/or anti fungal agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry C Lands, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>McGill Uinversity Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael W Konstan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rainbow Babies and Children's Hospital/ University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center, Division of Pulmonary &amp; Critical Care Medicine</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of pulmonary, critical care and sleep medicine, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System, Joe DiMaggio Children's Hospital Cystic Fibrosis &amp; Pulmonary Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research Center</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Luke's CF Center of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center Cystic Fibrosis Research</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University, Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Minnesota Cystic Fibrosis Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center, NJ Adult Cystic Fibrosis Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers University Clinical Research Center, RW Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center, Doernbecher Children's Hospital, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Div of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine, John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory and Sleep Medicine, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Lung and Sleep, Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Respiratory Health, Harry Perkins Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Lung Research Institute at St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Center for Practice-Changing Research</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche de l'institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Essential Fatty Acids</keyword>
  <keyword>Inflammation resolution</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>Lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

